Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018223118) USE OF TETRANECTIN AND PEPTIDE AGONISTS TO TREAT INFLAMMATORY DISEASES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

What is claimed is:

1. A method of treating endotoxemia or sepsis in a subject comprising administering to the subject having endotoxemia or sepsis an amount of a tetranectin protein or a tetranectin peptide agonist effective to treat endotoxemia or sepsis in a subject.

2. A method of reducing the likelihood of death from endotoxemia or sepsis in a subject having endotoxemia or sepsis, the method comprising administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat endotoxemia or sepsis in a subject.

3. A method of reducing the likelihood of endotoxemia or sepsis developing in a subject comprising administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to reduce the likelihood of endotoxemia or sepsis developing in a subject.

4. A method of reducing development of sepsis-associated coagulation in a subject comprising administering to the subj ect an amount of tetranectin protein or a tetranectin peptide agonist effective to reduce the development of sepsis-associated coagulation in a subject.

5. A method of reducing development of fibrinolysis in a subject comprising administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to reduce the development of fibrinolysis in a subject.

6. The method of any of Claims 1 -5, wherein the subject is a human subject.

7. The method of any of Claims 1 -6, wherein the subject is 60 years or older, or is immunocompromised.

8. The method of any of Claims 1 -7, wherein the amount of tetranectin protein is administered and the tetranectin protein is a recombinantly produced tetranectin protein .

9. The method of any of Claims 1-8, wherein the amount of tetranectin protein is administered and the tetranectin protein has the sequence of a human tetranectin protein but is not isolated from, or produced in, a human.

10. The method of any of Claims 1-7, wherein the amount of tetranectin peptide agonist is administered.

11. The method of Claim 10, wherein the tetranectin peptide agonist comprises a sequence of a plasminogen-binding region of a tetranectin protein.

12. The method of Claim 10 or 11, wherein the amount of tetranectin peptide agonist comprises a N-terminal deletion of tetranectin protein.

13. The method of any of Claims 1-12, further comprising one or more additional administration(s) of an amount of tetranectin protein or of tetranectin peptide agonist subsequent to the first administration.

14. A method of eliciting production of a neutrophil-attracting chemokine in a subject comprising administering to the subject an amount of a tetranectin protein or a tetranectin peptide agonist effective to elicit production of a neutrophil-attracting chemokine.

15. The method of Claim 14, wherein the neutrophil-attracting chemokine is

CXCLl/GRO-a/KC or CXCL5/ENA-78.

16. A method of treating an inflammatory disease in a subject comprising administering to the subject an amount of a tetranectin protein or a tetranectin peptide agonist effective to treat an inflammatory disease in a subject.

17. The method of Claim 14, 15 or 16, wherein the amount of tetranectin protein is administered and the tetranectin protein is a recombinantly produced tetranectin peptide.

18. The method of any of Claims 14-17, wherein the amount of tetranectin protein is administered and the tetranectin protein has the sequence of a human tetranectin protein but is not isolated from, or produced in, a human.

19. The method of any of Claims 14-18, wherein the amount of tetranectin peptide agonist is administered.

20. The method of Claim 19, wherein the tetranectin peptide agonist comprises a sequence of a plasminogen-binding region of a tetranectin protein.

21. The method of Claim 19 or 20, wherein the amount of tetranectin peptide agonist comprises a N-terminal deletion of tetranectin protein.